Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A post hoc Analysis from the Randomized VERTIS CV Trial

INTRODUCTION: Using data from the VERTIS CV trial (NCT01986881), the impact of ertugliflozin in patients with nonalbuminuric diabetic kidney disease (DKD-non-Alb) was assessed. METHODS: Patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD) were randomized t...

Descripción completa

Detalles Bibliográficos
Autores principales: Cherney, David Z.I., Dagogo-Jack, Samuel, Cosentino, Francesco, Pratley, Richard E., Frederich, Robert, Maldonado, Mario, Liu, Chih-Chin, Cannon, Christopher P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366295/
https://www.ncbi.nlm.nih.gov/pubmed/35967112
http://dx.doi.org/10.1016/j.ekir.2022.05.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366295/
https://www.ncbi.nlm.nih.gov/pubmed/35967112
http://dx.doi.org/10.1016/j.ekir.2022.05.007

Ejemplares similares